Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Acquires Rights to Scoliosis Prognostic Test

NEW YORK (GenomeWeb News) - Transgenomic today said that it has signed a definitive agreement to acquire the global rights to a multi-gene prognostic test for scoliosis from Axial Biotech.

The Omaha, Neb.-based molecular diagnostics firm bought the rights to Axial's ScoliScore Adolescent Idiopathic Scoliosis (AIS) Prognostic Test for $4.4 million in cash. The clinically validated and commercially available test uses saliva as a sample to look for multiple genes that provide a "highly accurate" assessment of the likelihood of spinal curve progression for children diagnosed with AIS, said Transgenomic.

"The ScoliScore Test identifies, with a high degree of accuracy, those individuals who are unlikely to progress to a point where surgery is needed, which can significantly reduce their radiation exposure from repeated x-ray monitoring," Transgenomic CEO Craig Tuttle said in a statement.

He noted that he expects the test to contribute positively to the firm's earnings by the end of 2012, excluding any acquisition related charges.

The firms did not disclose sales figures for the test, but Transgenomic said that it provides access to a market estimated at 400,000 patients in the US.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.